标题
Targeting the DNA damage response for cancer therapy
作者
关键词
-
出版物
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume -, Issue -, Pages -
出版商
Portland Press Ltd.
发表日期
2023-01-06
DOI
10.1042/bst20220681
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Inhibitors of PARP: Number crunching and structure gazing
- (2022) Johannes Rudolph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer
- (2022) Mary Smithson et al. NEOPLASIA
- Targeting DNA repair with combined inhibition of NHEJ and MMEJ induces synthetic lethality in TP53-mutant cancers
- (2022) Jeffrey Patterson-Fortin et al. CANCER RESEARCH
- Preclinical characterization of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper
- (2022) Giuditta Illuzzi et al. CLINICAL CANCER RESEARCH
- Hallmarks of DNA replication stress
- (2022) Sneha Saxena et al. MOLECULAR CELL
- Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
- (2022) Minsuk Kwon et al. Journal for ImmunoTherapy of Cancer
- The regulation of DNA end resection by chromatin response to DNA double strand breaks
- (2022) Bo-Ruei Chen et al. Frontiers in Cell and Developmental Biology
- Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy
- (2022) Santu Saha et al. Cancers
- Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
- (2021) Francesco Schettini et al. EUROPEAN JOURNAL OF CANCER
- Pamiparib: First Approval
- (2021) Anthony Markham DRUGS
- Fuzuloparib: First Approval
- (2021) Arnold Lee DRUGS
- ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
- (2021) Susana Banerjee et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Cell cycle control in cancer
- (2021) Helen K. Matthews et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Mechanism, cellular functions and cancer roles of polymerase-theta-mediated DNA end joining
- (2021) Dale A. Ramsden et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma
- (2021) Sumanta K. Pal et al. JAMA Oncology
- Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer
- (2021) Paula Pellenz Tomasini et al. Cancers
- Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
- (2021) R. Kim et al. ANNALS OF ONCOLOGY
- Targeting Non-homologous and Alternative End Joining Repair to Enhance Cancer Radiosensitivity
- (2021) Wanjuan Feng et al. SEMINARS IN RADIATION ONCOLOGY
- PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
- (2021) Amelia Barcellini et al. Cancers
- One end to rule them all: Non-homologous end-joining and homologous recombination at DNA double-strand breaks
- (2020) Michael Ensminger et al. BRITISH JOURNAL OF RADIOLOGY
- Targeting DNA-PK in cancer
- (2020) Giovanna Damia MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Biomarker-Guided Development of DNA Repair Inhibitors
- (2020) James M. Cleary et al. MOLECULAR CELL
- The 6-4 photoproduct is the trigger of UV-induced replication blockage and ATR activation
- (2020) Kai-Feng Hung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
- (2020) Hannah L Smith et al. Cancers
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib ( LY2606368 ) in BRCA Wild‐Type , Advanced Triple‐Negative Breast Cancer
- (2020) Margaret E. Gatti‐Mays et al. ONCOLOGIST
- ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
- (2020) R.E. Miller et al. ANNALS OF ONCOLOGY
- Poly(ADP-ribose) polymerase inhibition: past, present and future
- (2020) Nicola J. Curtin et al. NATURE REVIEWS DRUG DISCOVERY
- PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
- (2020) Maddison Rose et al. Frontiers in Cell and Developmental Biology
- A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
- (2020) Mark T. J. van Bussel et al. BRITISH JOURNAL OF CANCER
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
- (2019) Rachel M. Hurley et al. GYNECOLOGIC ONCOLOGY
- Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.
- (2019) Arjun Mittra et al. JOURNAL OF CLINICAL ONCOLOGY
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Inflammation-induced DNA damage, mutations and cancer
- (2019) Jennifer Kay et al. DNA REPAIR
- ATM in DNA repair in cancer
- (2019) Mei Hua Jin et al. PHARMACOLOGY & THERAPEUTICS
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
- (2019) Kalindi Parmar et al. CLINICAL CANCER RESEARCH
- Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically.
- (2019) Lucy C. Riches et al. MOLECULAR CANCER THERAPEUTICS
- Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
- (2019) Nicola J. Curtin et al. Nature Reviews Clinical Oncology
- Synthetic lethality as an engine for cancer drug target discovery
- (2019) Alan Huang et al. NATURE REVIEWS DRUG DISCOVERY
- First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
- (2019) Pamela Munster et al. Cancer Management and Research
- The relationship between DNA single-stranded damage response and double-stranded damage response
- (2018) Aiqing Ma et al. CELL CYCLE
- Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
- (2018) Nader Sanai et al. CLINICAL CANCER RESEARCH
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- Endogenous DNA Double-Strand Breaks during DNA Transactions: Emerging Insights and Methods for Genome-Wide Profiling
- (2018) Britta A. M. Bouwman et al. Genes
- Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
- (2017) Jonathan A. Webster et al. LEUKEMIA RESEARCH
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- Ataxia telangiectasia: a review
- (2016) Cynthia Rothblum-Oviatt et al. Orphanet Journal of Rare Diseases
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Exploiting DNA mismatch repair deficiency as a therapeutic strategy
- (2014) Delphine Guillotin et al. EXPERIMENTAL CELL RESEARCH
- Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
- (2013) M. A. Batey et al. MOLECULAR CANCER THERAPEUTICS
- Inconsistency in large pharmacogenomic studies
- (2013) Benjamin Haibe-Kains et al. NATURE
- The ATM protein kinase: regulating the cellular response to genotoxic stress and more
- (2013) Yosef Shiloh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Double-strand break repair: 53BP1 comes into focus
- (2013) Stephanie Panier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
- (2012) Remko Prevo et al. CANCER BIOLOGY & THERAPY
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
- (2010) Dana V. Ferraris JOURNAL OF MEDICINAL CHEMISTRY
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- FANCM and FAAP24 Function in ATR-Mediated Checkpoint Signaling Independently of the Fanconi Anemia Core Complex
- (2008) Spencer J. Collis et al. MOLECULAR CELL
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now